vs

Side-by-side financial comparison of Vivos Therapeutics, Inc. (VVOS) and Xos, Inc. (XOS). Click either name above to swap in a different company.

Xos, Inc. is the larger business by last-quarter revenue ($5.2M vs $3.8M, roughly 1.4× Vivos Therapeutics, Inc.). Vivos Therapeutics, Inc. runs the higher net margin — -180.3% vs -186.8%, a 6.6% gap on every dollar of revenue. On growth, Vivos Therapeutics, Inc. posted the faster year-over-year revenue change (3.4% vs -54.5%). Over the past eight quarters, Vivos Therapeutics, Inc.'s revenue compounded faster (5.8% CAGR vs -35.7%).

Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.

Xos, Inc. is an American manufacturer of commercial electric vehicles (EVs) and mobile EV chargers.

VVOS vs XOS — Head-to-Head

Bigger by revenue
XOS
XOS
1.4× larger
XOS
$5.2M
$3.8M
VVOS
Growing faster (revenue YoY)
VVOS
VVOS
+57.9% gap
VVOS
3.4%
-54.5%
XOS
Higher net margin
VVOS
VVOS
6.6% more per $
VVOS
-180.3%
-186.8%
XOS
Faster 2-yr revenue CAGR
VVOS
VVOS
Annualised
VVOS
5.8%
-35.7%
XOS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
VVOS
VVOS
XOS
XOS
Revenue
$3.8M
$5.2M
Net Profit
$-6.9M
$-9.8M
Gross Margin
78.1%
-50.5%
Operating Margin
-166.8%
-186.6%
Net Margin
-180.3%
-186.8%
Revenue YoY
3.4%
-54.5%
Net Profit YoY
-143.8%
48.6%
EPS (diluted)
$-0.58
$-0.76

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
VVOS
VVOS
XOS
XOS
Q4 25
$3.8M
$5.2M
Q3 25
$6.8M
$16.5M
Q2 25
$3.8M
$18.4M
Q1 25
$3.0M
$5.9M
Q4 24
$3.7M
$11.5M
Q3 24
$3.9M
$15.8M
Q2 24
$4.1M
$15.5M
Q1 24
$3.4M
$12.6M
Net Profit
VVOS
VVOS
XOS
XOS
Q4 25
$-6.9M
$-9.8M
Q3 25
$-5.4M
$2.1M
Q2 25
$-5.0M
$-7.5M
Q1 25
$-3.9M
$-10.2M
Q4 24
$-2.8M
$-19.0M
Q3 24
$-2.6M
$-10.5M
Q2 24
$-1.9M
$-9.7M
Q1 24
$-3.8M
$-11.0M
Gross Margin
VVOS
VVOS
XOS
XOS
Q4 25
78.1%
-50.5%
Q3 25
58.0%
15.3%
Q2 25
55.2%
8.8%
Q1 25
50.0%
20.6%
Q4 24
56.7%
-32.4%
Q3 24
60.5%
18.1%
Q2 24
65.4%
13.1%
Q1 24
56.7%
22.1%
Operating Margin
VVOS
VVOS
XOS
XOS
Q4 25
-166.8%
-186.6%
Q3 25
-69.8%
-42.4%
Q2 25
-127.4%
-38.5%
Q1 25
-129.9%
-157.7%
Q4 24
-75.9%
-127.0%
Q3 24
-68.5%
-61.4%
Q2 24
-47.8%
-73.2%
Q1 24
-110.7%
-81.1%
Net Margin
VVOS
VVOS
XOS
XOS
Q4 25
-180.3%
-186.8%
Q3 25
-79.6%
12.9%
Q2 25
-131.2%
-40.8%
Q1 25
-128.1%
-173.3%
Q4 24
-76.4%
-165.4%
Q3 24
-67.8%
-66.6%
Q2 24
-47.6%
-62.2%
Q1 24
-110.1%
-87.1%
EPS (diluted)
VVOS
VVOS
XOS
XOS
Q4 25
$-0.58
$-0.76
Q3 25
$-0.49
$0.22
Q2 25
$-0.55
$-0.91
Q1 25
$-0.45
$-1.26
Q4 24
$0.41
$-2.34
Q3 24
$-0.40
$-1.32
Q2 24
$-0.60
$-1.23
Q1 24
$-1.63
$-1.80

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
VVOS
VVOS
XOS
XOS
Cash + ST InvestmentsLiquidity on hand
$2.0M
$14.0M
Total DebtLower is stronger
$2.9M
Stockholders' EquityBook value
$-1.5M
$23.3M
Total Assets
$25.2M
$60.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
VVOS
VVOS
XOS
XOS
Q4 25
$2.0M
$14.0M
Q3 25
$3.1M
$14.1M
Q2 25
$4.4M
$8.8M
Q1 25
$2.3M
$4.8M
Q4 24
$6.3M
$11.0M
Q3 24
$6.3M
$8.4M
Q2 24
$6.9M
$19.7M
Q1 24
$2.6M
$46.2M
Total Debt
VVOS
VVOS
XOS
XOS
Q4 25
$2.9M
Q3 25
Q2 25
Q1 25
Q4 24
$1.2M
Q3 24
$1.2M
Q2 24
$1.2M
Q1 24
Stockholders' Equity
VVOS
VVOS
XOS
XOS
Q4 25
$-1.5M
$23.3M
Q3 25
$2.5M
$31.1M
Q2 25
$4.6M
$18.3M
Q1 25
$4.4M
$24.8M
Q4 24
$8.0M
$33.6M
Q3 24
$7.7M
$50.8M
Q2 24
$6.3M
$59.2M
Q1 24
$582.0K
$67.8M
Total Assets
VVOS
VVOS
XOS
XOS
Q4 25
$25.2M
$60.4M
Q3 25
$25.6M
$73.8M
Q2 25
$26.0M
$80.3M
Q1 25
$11.3M
$87.7M
Q4 24
$15.3M
$98.3M
Q3 24
$15.3M
$120.5M
Q2 24
$15.8M
$123.4M
Q1 24
$11.8M
$135.0M
Debt / Equity
VVOS
VVOS
XOS
XOS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.15×
Q3 24
0.16×
Q2 24
0.19×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
VVOS
VVOS
XOS
XOS
Operating Cash FlowLast quarter
$-3.8M
$2.4M
Free Cash FlowOCF − Capex
$-5.3M
FCF MarginFCF / Revenue
-139.7%
Capex IntensityCapex / Revenue
40.0%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-17.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
VVOS
VVOS
XOS
XOS
Q4 25
$-3.8M
$2.4M
Q3 25
$-4.2M
$3.1M
Q2 25
$-3.5M
$4.6M
Q1 25
$-3.8M
$-4.8M
Q4 24
$-2.9M
$3.3M
Q3 24
$-4.2M
$-11.5M
Q2 24
$-3.0M
$-26.0M
Q1 24
$-2.5M
$-14.6M
Free Cash Flow
VVOS
VVOS
XOS
XOS
Q4 25
$-5.3M
Q3 25
$-4.2M
Q2 25
$-4.3M
Q1 25
$-3.9M
Q4 24
$-3.1M
Q3 24
$-4.4M
$-11.7M
Q2 24
$-3.1M
$-26.1M
Q1 24
$-2.7M
$-14.6M
FCF Margin
VVOS
VVOS
XOS
XOS
Q4 25
-139.7%
Q3 25
-62.6%
Q2 25
-111.6%
Q1 25
-129.9%
Q4 24
-84.0%
Q3 24
-113.4%
-73.9%
Q2 24
-76.7%
-168.1%
Q1 24
-78.0%
-115.7%
Capex Intensity
VVOS
VVOS
XOS
XOS
Q4 25
40.0%
0.0%
Q3 25
1.2%
0.0%
Q2 25
20.2%
0.0%
Q1 25
4.0%
0.0%
Q4 24
4.5%
0.0%
Q3 24
5.0%
0.9%
Q2 24
1.5%
0.8%
Q1 24
4.4%
0.2%
Cash Conversion
VVOS
VVOS
XOS
XOS
Q4 25
Q3 25
1.45×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

VVOS
VVOS

Services$3.2M84%
Products$594.0K16%

XOS
XOS

Segment breakdown not available.

Related Comparisons